Cargando…

Systemic sclerosis in the time of COVID-19

The COVID-19 pandemic represents one of the biggest challenges of the 21st century. In addition to the general effect on society and health-care systems, patients with systemic sclerosis and their physicians face specific challenges related to the chronic nature of their disease, the involvement of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hoffmann-Vold, Anna-Maria, Distler, Oliver, Bruni, Cosimo, Denton, Christopher P, de Vries-Bouwstra, Jeska, Matucci Cerinic, Marco, Vonk, Madelon C, Gabrielli, Armando
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Published by Elsevier Ltd. 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9302939/ https://www.ncbi.nlm.nih.gov/pubmed/35891634 http://dx.doi.org/10.1016/S2665-9913(22)00130-8

Ejemplares similares

COVID-19 and systemic sclerosis: Rising to the challenge of a pandemic
por: Denton, Christopher P, et al.
Publicado: (2020)

Treatment of systemic sclerosis: is there any hope for the future?
por: Allanore, Yannick, et al.
Publicado: (2016)

Requirements for systemic sclerosis expert centres in the Netherlands: A Delphi consensus study
por: Spierings, Julia, et al.
Publicado: (2020)

Patient perception of disease burden in diffuse cutaneous systemic sclerosis
por: Khanna, Dinesh, et al.
Publicado: (2019)

Sex-specific difference in cardiac function in patients with systemic sclerosis: association with cardiovascular outcomes
por: Gegenava, Tea, et al.
Publicado: (2023)

Factors influencing early referral, early diagnosis and management in patients with diffuse cutaneous systemic sclerosis
por: Distler, Oliver, et al.
Publicado: (2018)

Anticentromere Antibody Levels and Isotypes and the Development of Systemic Sclerosis
por: van Leeuwen, Nina M., et al.
Publicado: (2021)

Interleukin-1 and Systemic Sclerosis: Getting to the Heart of Cardiac Involvement
por: De Luca, Giacomo, et al.
Publicado: (2021)

The Treatment of Lung Involvement in Systemic Sclerosis
por: Ruaro, Barbara, et al.
Publicado: (2021)

Phenotypes Determined by Cluster Analysis and Their Survival in the Prospective European Scleroderma Trials and Research Cohort of Patients With Systemic Sclerosis
por: Sobanski, Vincent, et al.
Publicado: (2019)

Open questions on the management of targeted therapies for the treatment of systemic sclerosis-interstitial lung disease: results of a EUSTAR survey based on a systemic literature review
por: Campochiaro, Corrado, et al.
Publicado: (2022)

Gastrointestinal symptom severity and progression in systemic sclerosis
por: van Leeuwen, Nina M, et al.
Publicado: (2022)

Patient preferences for the treatment of systemic sclerosis-associated interstitial lung disease: a discrete choice experiment
por: Bruni, Cosimo, et al.
Publicado: (2022)

Heterogeneity of determining disease severity, clinical course and outcomes in systemic sclerosis-associated interstitial lung disease: a systematic literature review
por: Petelytska, Liubov, et al.
Publicado: (2023)

Computed Tomography Predictors of Mortality or Disease Progression in Systemic Sclerosis–Interstitial Lung Disease: A Systematic Review
por: Landini, Nicholas, et al.
Publicado: (2022)

Registry Evaluation of Digital Ulcers in Systemic Sclerosis
por: Galluccio, Felice, et al.
Publicado: (2010)

Predictors of disease worsening defined by progression of organ damage in diffuse systemic sclerosis: a European Scleroderma Trials and Research (EUSTAR) analysis
por: Becker, Mike, et al.
Publicado: (2019)

Association of Anti–Topoisomerase I Antibodies of the IgM Isotype With Disease Progression in Anti–Topoisomerase I–Positive Systemic Sclerosis
por: Boonstra, Maaike, et al.
Publicado: (2020)

IL-21R mRNA is overexpressed in systemic sclerosis and contributes to the epidermal/dermal cross-talk
por: Distler, O, et al.
Publicado: (2003)

Nintedanib in Patients With Systemic Sclerosis–Associated Interstitial Lung Disease: Subgroup Analyses by Autoantibody Status and Modified Rodnan Skin Thickness Score
por: Kuwana, Masataka, et al.
Publicado: (2022)

Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the European Scleroderma Trials and Research (EUSTAR) cohort
por: Wu, Wanlong, et al.
Publicado: (2019)

The “myth” of loss of angiogenesis in systemic sclerosis: a pivotal early pathogenetic process or just a late unavoidable event?
por: Matucci-Cerinic, Marco, et al.
Publicado: (2017)

From “being at war” to “getting back on your feet”: A qualitative study on experiences of patients with systemic sclerosis treated with hematopoietic stem cell transplantation
por: Spierings, Julia, et al.
Publicado: (2020)

Health-related quality of life in patients with systemic sclerosis: evolution over time and main determinants
por: van Leeuwen, Nina M, et al.
Publicado: (2021)

The Role of Bronchoalveolar Lavage in Systemic Sclerosis Interstitial Lung Disease: A Systematic Literature Review
por: Orlandi, Martina, et al.
Publicado: (2022)

Elucidating the burden of recurrent and chronic digital ulcers in systemic sclerosis: long-term results from the DUO Registry
por: Matucci-Cerinic, Marco, et al.
Publicado: (2016)

Treatment decision-making in diffuse cutaneous systemic sclerosis: a patient’s perspective
por: Spierings, Julia, et al.
Publicado: (2020)

The Prognostic Value of Right Atrial and Right Ventricular Functional Parameters in Systemic Sclerosis
por: Vos, Jacqueline L., et al.
Publicado: (2022)

Predictors of progression in systemic sclerosis patients with interstitial lung disease
por: Distler, Oliver, et al.
Publicado: (2020)

Clinical characteristics and predictors of gangrene in patients with systemic sclerosis and digital ulcers in the Digital Ulcer Outcome Registry: a prospective, observational cohort
por: Allanore, Yannick, et al.
Publicado: (2016)

Demographic, clinical and antibody characteristics of patients with digital ulcers in systemic sclerosis: data from the DUO Registry
por: Denton, Christopher P, et al.
Publicado: (2012)

OTUD6B-AS1 Might Be a Novel Regulator of Apoptosis in Systemic Sclerosis
por: Takata, Miki, et al.
Publicado: (2019)

The crowded crossroad to angiogenesis in systemic sclerosis: where is the key to the problem?
por: Manetti, Mirko, et al.
Publicado: (2016)

Systemic sclerosis: state of the art on clinical practice guidelines
por: Smith, Vanessa, et al.
Publicado: (2018)

Impact of lung function and baseline clinical characteristics on patient-reported outcome measures in systemic sclerosis-associated interstitial lung disease
por: Kreuter, Michael, et al.
Publicado: (2022)

Cyclophosphamide in systemic sclerosis: still in search of a 'real life' scenario
por: Miniati, Irene, et al.
Publicado: (2009)

Pulmonary veno-occlusive disease in a patient with recently diagnosed systemic sclerosis
por: van Leeuwen, Nina M, et al.
Publicado: (2019)

Systemic sclerosis-associated pulmonary hypertension: why disease-specific composite endpoints are needed
por: Denton, Christopher P, et al.
Publicado: (2011)

The systemic sclerosis patient in the COVID-19 era: the challenging crossroad between immunosuppression, differential diagnosis and long-term psychological distress
por: Orlandi, Martina, et al.
Publicado: (2020)

Proangiogenic effects of soluble α-Klotho on systemic sclerosis dermal microvascular endothelial cells
por: Mazzotta, Celestina, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_tka1ghtlmmji4etur46a1pf7dj